{
    "nctId": "NCT03791736",
    "briefTitle": "Evaluation of Impact of Sandostatin\u00ae Injection Before Axillary Clearance on Lymphocele Formation",
    "officialTitle": "Evaluation of Impact of Sandostatin\u00ae Injection Before Axillary Clearance on Lymphocele Formation In Patients With Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Lymphocele",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "A 50% decrease in the incidence of lymphocele (30% to 15% progression) following axillary clearance of patients operated for breast cancer (excluding mastectomy) pretreated with an injection of Sandostatin\u00ae.",
    "eligibilityCriteria": "Inclusion Criteria:\n\nBreast cancer, histologically proven Axillary clearance Elective axillary approach Age \u2265 18 years OMS \\< 3 Normal hematological and hepatic blood tests Obtaining the signed written consent of the patient\n\nExclusion Criteria:\n\nAxillary clearance with a mastectomy Metastatic disease Disorder precluding understanding of trial information or informed consent Pregnancy, breastfeeding women Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations No severe or uncontrolled diabetes Known hypersensitivity to Octreotide Patient with vitamin B12 deficiency Anticoagulant treatment History of cardiovascular disease Other product being tested in the 4 weeks prior to the start of treatment Patient has valid health insurance",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}